Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Apr 20217:09 amRNSDMS central to improved safety on US roads
26th Apr 20217:00 amRNSDMS award brings OEM customer count to seven
31st Mar 20217:00 amRNSHalf-year results and financial report
22nd Mar 20217:00 amRNSIssue of shares and total voting rights
19th Mar 20217:16 amRNSNotice of Results and Investor Presentation
8th Feb 20217:00 amRNSSEE DMS Available in 2021 Cadillac Escalade
3rd Feb 20217:30 amRNSHolding(s) in Company
1st Feb 20217:00 amRNSHalf year trading update
27th Jan 20217:00 amRNSQualcomm and Seeing Machines collaboration
13th Jan 20214:41 pmRNSSecond Price Monitoring Extn
13th Jan 20214:35 pmRNSPrice Monitoring Extension
13th Jan 20218:48 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSLicense Agreement with OmniVision Technologies
22nd Dec 20207:00 amRNSFleet Update
30th Nov 20209:19 amRNS2020 AGM Results and Board Changes
25th Nov 202011:50 amRNSDirector/PDMR Shareholding
23rd Nov 202010:00 amRNSShare Transfer & Issue of Performance Rights
5th Nov 20208:02 amRNSNotice of AGM
2nd Nov 202011:43 amRNSHolding(s) in Company
2nd Nov 20207:00 amRNSYear End Results
30th Oct 20209:19 amRNSHolding(s) in Company
30th Oct 20207:00 amRNSWebcast Presentation - Year End Results
29th Oct 202011:39 amRNSHolding(s) in Company
29th Oct 20207:00 amRNSHolding(s) in Company
23rd Oct 20207:00 amRNSIssue of Shares & Total Voting Rights
21st Oct 20207:00 amRNSSEE signs MOU with L3Harris Technologies
12th Oct 20207:00 amRNSSEE extends leading DMS to Occupant Monitoring
16th Sep 20207:15 amRNS5 billion kilometres of Guardian driving data
14th Sep 20207:00 amRNSLaunch of DMS Kit on Qualcomm Snapdragon Platform
8th Sep 20209:05 amRNSSecond Price Monitoring Extn
8th Sep 20209:00 amRNSPrice Monitoring Extension
8th Sep 20207:00 amRNSSEE signs MOU with leading Semiconductor Company
2nd Sep 20209:00 amRNSNext Gen Embedded Product Strategy for Auto DMS
14th Aug 202010:55 amRNSShare purchase by PCA of non-executive director
3rd Aug 20207:00 amRNSFY20 Trading Update
7th Jul 20207:00 amRNSUS set to mandate DMS from 2024
19th May 20207:00 amRNSBusiness restructure and Covid measures
14th May 20207:00 amRNSBoard Changes
6th May 202011:05 amRNSSecond Price Monitoring Extn
6th May 202011:00 amRNSPrice Monitoring Extension
5th May 20204:41 pmRNSSecond Price Monitoring Extn
5th May 20204:35 pmRNSPrice Monitoring Extension
14th Apr 20201:53 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSDirector/PDMR Shareholding
6th Apr 20204:40 pmRNSSecond Price Monitoring Extn
6th Apr 20204:35 pmRNSPrice Monitoring Extension
2nd Apr 20202:06 pmRNSSecond Price Monitoring Extn
2nd Apr 20202:00 pmRNSPrice Monitoring Extension
2nd Apr 202011:00 amRNSPrice Monitoring Extension
1st Apr 20204:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.